As shown in Figure 5A and Table S4, the rectal tumors displayed a higher ratio of KRAS G12 mutations (G12D 34%, G12V 27%, G12A 9%, G12C 3%) compared to the tumors from the colon. This evidence concerns the gene KRAS and rectal neoplasm.